Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [5] - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive therapies [5] - Currently, Aquestive has four commercialized products marketed by its licensees globally and is the exclusive manufacturer of these products [5] Offering Details - The company announced an underwritten offering of 21,250,000 shares of common stock at a price of $4.00 per share, expecting gross proceeds of $85 million before expenses [1] - The net proceeds will primarily be used to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for treating severe allergic reactions, pending FDA approval [1] - The offering is expected to close around August 15, 2025, subject to customary closing conditions [1] Underwriters and Management - The offering was led by RTW Investments, LP, with participation from several investment firms including Samsara BioCapital and EcoR1 Capital [2] - Leerink Partners, Cantor, and Oppenheimer & Co. are acting as joint bookrunning managers, while H.C. Wainwright & Co. is the lead manager [2] Regulatory Information - A shelf registration statement relating to the offering was filed with the SEC and declared effective on April 23, 2024 [3] - A final prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3]

commercialization of Anaphylm for the emergency treatment of allergic reactions, including anaphylaxis WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP ("RTW"), subject to United States F ...

Corporate Presentation September 2024 August 2025 Solving problems. Improving lives. Advancing medicines. Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. ("Aquestive", the "Company", "our" or "us") and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and ...

A live webcast of the call will be available on the Investors section of Aquestive's website at: Second Quarter 2025 Earnings Call Following the call, a replay of the webcast will be available on the Investors section of the Company's website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days. About Aquestive Therapeutics Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science a ...

WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the promotion of Sherry Korczynski, from Senior Vice President of Sales and Marketing, to Chief Commercial Officer effective July 22, 2025. "Sherry's promotion reflects her exceptional track record in commercial leadership ...

Unlike traditional epinephrine auto-injectors that require needles, Anaphylm™ is administered orally, addressing critical barriers to treatment, including needle phobia, device malfunction concerns, and portability challenges that affect patient compliance and emergency response. The Company's ex-U.S. regulatory strategy prioritizes markets with significant unmet medical needs and regulatory frameworks conducive to innovative therapies. EMA and Canada represent ideal initial international markets given thei ...

Core Insights - Aquestive Therapeutics, Inc. announced two poster presentations on Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit, highlighting its potential as the first orally delivered epinephrine option for severe allergic reactions in the U.S. [1] Group 1: Product Details - Anaphylm™ is a polymer matrix-based epinephrine prodrug that is small, lightweight, and dissolves on contact without the need for water or swallowing [3] - The product's packaging is designed to be portable and weather-resistant, making it convenient for users [3] - Anaphylm has received conditional approval for its trade name from the FDA, pending final product approval [3] Group 2: Presentation Information - The first poster presentation focuses on the physicochemical properties of Anaphylm under extreme temperatures and real-world conditions, led by Nils Confer, PhD [2] - The second poster presentation discusses the pharmacokinetic and pharmacodynamic responses of Anaphylm, led by Carl Kraus, MD [2] Group 3: Company Overview - Aquestive Therapeutics is dedicated to advancing medicines through innovative science and delivery technologies, with a focus on orally administered products [4] - The company has four commercialized products and collaborates with other pharmaceutical companies to bring new molecules to market [4] - In addition to Anaphylm, the company is developing an earlier-stage epinephrine prodrug topical gel for dermatological conditions [4]

Core Viewpoint - Aquestive Therapeutics, Inc. is actively participating in the Citizens Life Sciences Conference, indicating its commitment to engaging with investors and showcasing its innovative pharmaceutical developments [1][2]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines that significantly improve patients' lives through innovative science and delivery technologies [3]. - The company is developing orally administered and topical gel products aimed at delivering complex molecules, providing alternatives to traditional therapies [3]. - Currently, Aquestive has four commercialized products marketed by licensees in the U.S. and globally, and it serves as the exclusive manufacturer of these products [3]. - The company collaborates with other pharmaceutical firms to bring new molecules to market using proprietary technologies, such as PharmFilm® [3]. Product Development - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [3]. - An early-stage epinephrine prodrug topical gel product candidate is also in development for various dermatological conditions, including alopecia areata [3]. Upcoming Events - The management team will hold a fireside chat on May 8 at 10 am ET during the Citizens Life Sciences Conference, along with one-on-one meetings with investors [2]. - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [2].

Company Overview - Aquestive Therapeutics, Inc. is a pharmaceutical company focused on advancing medicines to improve patients' lives through innovative science and delivery technologies [4] - The company is developing orally administered products to deliver complex molecules, providing alternatives to invasive therapies [4] - Currently, Aquestive has four commercialized products marketed by its licensees in the U.S. and globally, and it is the exclusive manufacturer of these products [4] Recent Developments - The company will report its first-quarter results for the period ended March 31, 2025, and provide business updates on May 12, 2025, after market close [1] - A conference call for investors is scheduled for May 13, 2025, at 8:00 a.m. ET, with a live webcast available on the company's website [2] Product Pipeline - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis [4] - The company is also developing an earlier-stage epinephrine prodrug topical gel for dermatological conditions such as alopecia areata [4]

Core Insights - Aquestive Therapeutics announced positive topline results from its pediatric study for Anaphylm™ (epinephrine) sublingual film, indicating its potential as a treatment for severe allergic reactions in patients aged seven to seventeen [1][2] - The company has submitted the New Drug Application (NDA) for Anaphylm to the FDA, with expectations for acceptance in the second quarter of 2025 [1][6] - If approved, Anaphylm is planned to be launched in the first quarter of 2026 [2] Pediatric Study Results - The pediatric study was a multi-site, single treatment study involving thirty-two patients, demonstrating consistent pharmacokinetic (PK) profiles with previous adult studies [2] - Anaphylm was found to be safe and well-tolerated, with no serious adverse events reported [2] Product Overview - Anaphylm is a polymer matrix-based epinephrine prodrug designed for the treatment of severe allergic reactions, including anaphylaxis [3] - The product is compact, similar in size to a postage stamp, and does not require water or swallowing for administration [3] Company Background - Aquestive Therapeutics focuses on advancing medicines through innovative science and delivery technologies, with five commercialized products and collaborations with other pharmaceutical companies [4] - The company is also developing an earlier stage epinephrine prodrug topical gel for dermatological conditions [4]